Sex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans

Nicotine and Tobacco Research

Volumn 12, Issue 3, 2010, Pages 251-262

  David, Sean P ^a   Mezuk, Briana ^b   Zandi, Peter P ^c   Strong, David ^d   Anthony, James C ^e   Niaura, Raymond ^d   Uhl, George R ^f   Eaton, William W ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d BROWN UNIVERSITY   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANKYRIN REPEAT AND KINASE CONTAINING 1; DOPAMINE 2 RECEPTOR; GENE PRODUCT; TETRATRICOPEPTIDE REPEAT DOMAIN PROTEIN 12; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; INTERVIEW; LONGITUDINAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION; UNITED STATES;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; PROTEINS; SEX CHARACTERISTICS; SMOKING;

EID: 77950253847     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntp201     Document Type: Article

References (55)

1. Abrous, D. N., Adriani, W., Montaron, M. F., Aurousseau, C., Rougon, G., Le Moal, M., et al. (2002). Nicotine selfadministration impairs hippocampal plasticity. Journal of Neuroscience, 22, 3656-3662.
2. Breen, G., Brown, J., Maude, S., Fox, H., Collier, D., Li, T., et al. (1999). -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. American Journal of Medical Genetics, 88, 407-410.
3. Burkett, K., Graham, J., & McNeney, B. (2006). hapassoc: Software for likelihood inference of trait associations with SNP haplotypes and other attributes. Journal of Statistical Software, 16(2), 1-19.
4. Caraballo, R. S., Yee, S. L., Gfroerer, J., & Mirza, S. A. (2008). Adult tobacco use among racial and ethnic groups living in the United States, 2002-2005. Preventing Chronic Disease, 5, A78.
5. Centers for Disease Control and Prevention. (1998). Tobacco use among U.S. racial/ethnic minority groups-African Americans, American Indians and Alaska Natives, Asian Americans and Pacific Islanders, Hispanics. A report of the Surgeon General. Executive summary. Morbidity and Mortality Weekly Reports. Recommendations and Reports, 47(RR-18), v-xv. 1-16.
6. Centers for Disease Control and Prevention. (2002). Women and smoking: A report of the Surgeon General. Executive summary. Morbidity and Mortality Weekly Report. Recommendations and Reports, 51(RR-12), i-iv. 1-13.
7. Cepeda-Benito, A., Reynoso, J. T., & Erath, S. (2004). Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: Differences between men and women. Journal of Consulting and Clinical Psychology, 72, 712-722.
8. David, S. P., Brown, R. A., Papandonatos, G. D., Kahler, C. W., Lloyd-Richardson, E. E., Munafo, M. R., et al. (2007). Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine & Tobacco Research, 9, 821-833
9. David, S. P., & Munafo, M. R. (2008). Genetic variation in the dopamine pathway and smoking cessation. Pharmacogenomics, 9, 1307-1321.
10. David, S. P., Strong, D. R., Munafo, M. R., Brown, R. A., Lloyd-Richardson, E. E., Wileyto, P. E., et al. (2007). Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: Analysis of pooled data from two clinical trials. Nicotine & Tobacco Research, 9, 1251-1257.
11. Eaton, W. W., Kalaydjian, A., Scharfstein, D. O., Mezuk, B., & Ding, Y. (2007). Prevalence and incidence of depressive disorder: The Baltimore ECA follow-up, 1981-2004. Acta Psychiatrica Scandinavica, 116, 182-188.
12. Eaton, W. W., Neufeld, K., Chen, L. S., & Cai, G. (2000). A comparison of self-report and clinical diagnostic interviews for depression: Diagnostic interview schedule and schedules for clinical assessment in neuropsychiatry in the Baltimore epidemiologic catchment area follow-up. Archives of General Psychiatry, 57, 217-222.
13. Fu, S. S., Burgess, D. J., Hatsukami, D. K., Noorbaloochi, S., Clothier, B. A., Nugent, S., et al. (2008). Race and nicotine replacement treatment outcomes among low-income smokers. American Journal of Preventive Medicine, 35(Suppl. 6), S442-S448.
14. Fu, S. S., Kodl, M. M., Joseph, A. M., Hatsukami, D. K., Johnson, E. O., Breslau, N., et al. (2008). Racial/ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years. Cancer Epidemioly, Biomarkers and Prevention, 17, 1640-1647.
15. Gelernter, J., Yu, Y., Weiss, R., Brady, K., Panhuysen, C., Yang, B. Z., et al. (2006). Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations. Human Molecular Genetics, 15, 3498-3507.
16. Grandy, D. K., Litt, M., Allen, L., Bunzow, J. R., Marchionni, M., Makam, H., et al. (1989). The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. American Journal of Human Genetics, 45, 778-785.
17. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerstrom, K. O. (1991). The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
18. Johnson, C., Dragon, T., Liu, Q. R., Zhang, P. W., Walther, D., Li, C. Y., Anthony, J. C., et al. (2008). Biomed Central Medical Genetics, 9, 113.
19. Johnstone, E. C., Yudkin, P. L., Hey, K., Roberts, S. J., Welch, S. J., Murphy, M. F., et al. (2004). Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics, 14, 83-90.
20. Jonsson, E., Sedvall, G., Brene, S., Gustavsson, J. P., Geijer, T., Terenius, L., et al. (1996). Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biological Psychiatry, 40, 1032-1043.
21. Jonsson, E. G., Nothen, M. M., Grunhage, F., Farde, L., Nakashima, Y., Propping, P., et al. (1999). Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Molecular Psychiatry, 4, 290-296.
22. Katoh, M., & Katoh, M. (2003). Identification and characterization of TPARM gene in silico. International Journal of Oncology, 23, 1213-1217.
23. Kendzor, D. E., Cofta-Woerpel, L. M., Mazas, C. A., Li, Y., Vidrine, J. I., Reitzel, L. R., et al. (2008). Socioeconomic status, negative affect, and modifiable cancer risk factors in African-American smokers. Cancer Epidemiology, Biomarkers and Prevention, 17, 2546-2554.
24. Lerman, C., Jepson, C., Wileyto, E. P., Epstein, L. H., Rukstalis, M., Patterson, F., et al. (2006). Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: Results of two randomized clinical trials. Neuropsychopharmacology, 31, 231-242.
25. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Hawk, L. H., Jr., Pinto, A., et al. (2003). Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology, 22, 541-548.
26. Lerman, C., Shields, P. G., Wileyto, E. P., Audrain, J., Pinto, A., Hawk, L., et al. (2002). Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics, 12, 627-634.
27. Li, M. D., Cheng, R., Ma, J. Z., & Swan, G. E. (2003). A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction, 98, 23-31.
28. Li, M. D., Ma, J. Z., & Beuten, J. (2004). Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clinical Genetics, 66, 382-392.
29. Mezuk, B., Eaton, W. W., & Zandi, P. (2008). Participant characteristics that influence consent for genetic research in a population-based survey: The Baltimore epidemiologic catchment area follow-up. Community Genetics, 11, 171-178.
30. Munafo, M., Bradburn, M., Bowes, L., & David, S. (2004). Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine & Tobacco Research, 6, 769-776.
31. Munafo, M., Clark, T., Johnstone, E., Murphy, M., & Walton, R. (2004). The genetic basis for smoking behavior: A systematic review and meta-analysis. Nicotine & Tobacco Research, 6, 583-597.
32. Munafo, M. R., Timpson, N. J., David, S. P., Ebrahim, S., & Lawlor, D. A. (2009). Association of the DRD2 gene Taq1A polymorphism and smoking behavior: A meta-analysis and new data. Nicotine & Tobacco Research, 11, 64-76.
33. Neville, M. J., Johnstone, E. C., & Walton, R. T. (2004). Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation, 23, 540-545.
34. Nguyen, C., Mattei, M. G., Mattei, J. F., Santoni, M. J., Goridis, C., & Jordan, B. R. (1986). Localization of the human NCAM gene to band q23 of chromosome 11: The third gene coding for a cell interaction molecule mapped to the distal portion of the long arm of chromosome 11. Journal of Cell Biology, 102, 711-715.
35. Niaura, R., Shadel, W. G., Abrams, D. B., Monti, P. M., Rohsenow, D. J., & Sirota, A. (1998). Individual differences in cue reactivity among smokers trying to quit: Effects of gender and cue type. Addictive Behaviors, 23, 209-224.
36. Noble, E. P., Blum, K., Ritchie, T., Montgomery, A., & Sheridan, P. J. (1991). Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Archives of General Psychiatry, 48, 648-654.
37. Noble, E. P., Gottschalk, L. A., Fallon, J. H., Ritchie, T. L., & Wu, J. C. (1997). D2 dopamine receptor polymorphism and brain regional glucose metabolism. American Journal of Medical Genetics, 74, 162-166.
38. Perkins, K. A. (1999). Nicotine self-administration. Nicotine & Tobacco Research, 1(Suppl. 2), S133-S137; discussion S139-S140.
39. Perkins, K. A. (2001). Smoking cessation in women. Special considerations. Central Nervous System Drugs, 15, 391-411.
40. Perkins, K. A., D'Amico, D., Sanders, M., Grobe, J. E., Wilson, A., & Stiller, R. L. (1996). Influence of training dose on nicotine discrimination in humans. Psychopharmacology, 126, 132-139.
41. Perkins, K. A., & Scott, J. (2008). Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine & Tobacco Research, 10, 1245-1250.
42. Primack, B. A., Bost, J. E., Land, S. R., & Fine, M. J. (2007). Volume of tobacco advertising in African American markets: Systematic review and meta-analysis. Public Health Reports, 122, 607-615.
43. Regier, D. A., Myers, J. K., Kramer, M., Robins, L. N., Blazer, D. G., Hough, R. L., et al. (1984). The NIMH epidemiologic catchment area program. Historical context, major objectives, and study population characteristics. Archives of General Psychiatry, 41, 934-941.
44. Shi, M. M., Myrand, S. P., Bleavins, M. R., & de la Iglesia, F. A. (1999). High throughput genotyping for the detection of a single nucleotide polymorphism in NAD(P)H quinone oxidoreductase (DT diaphorase) using TaqMan probes. Molecular Pathology, 52, 295-299.
45. Swan, G. E., Jack, L. M., Valdes, A. M., Ring, H. Z., Ton, C. C., Curry, S. J., et al. (2007). Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychology, 26, 361-368.
46. Swan, G. E., Valdes, A. M., Ring, H. Z., Khroyan, T. V., Jack, L. M., Ton, C. C., et al. (2005). Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics Journal, 5, 21-29.
47. Uhl, G. R., Liu, Q. R., Drgon, T., Johnson, C., Walther, D., Rose, J. E., et al. (2008). Molecular genetics of successful smoking cessation: Convergent genome-wide association study results. Archives of General Psychiatry, 65, 683-693.
48. World Health Organization. (2009). Tobacco key facts. Retrieved 6 April 2009, from http://www.who.int/topics/tobacco/facts/en/index.html
49. Yang, B. Z., Kranzler, H. R., Zhao, H., Gruen, J. R., Luo, X., & Gelernter, J. (2007). Association of haplotypic variants in DRD2, ANKK1, TTC12 and NCAM1 to alcohol dependence in independent case control and family samples. Human Molecular Genetics, 16, 2844-2853.
50. Yang, B. Z., Kranzler, H. R., Zhao, H., Gruen, J. R., Luo, X., & Gelernter, J. (2008). Haplotypic variants in DRD2, ANKK1, TTC12, and NCAM1 are associated with comorbid alcohol and drug dependence. Alcoholism, Clinical and Experimental Research, 32, 2117-2127.
51. Yudkin, P., Munafo, M., Hey, K., Roberts, S., Welch, S., Johnstone, E., et al. (2004). Effectiveness of nicotine patches in relation to genotype in women versus men: Randomised controlled trial. British Medical Journal, 328, 989-990.
52. Zandi, P. P., Avramopoulos, D., Willour, V. L., Huo, Y., Miao, K., Mackinnon, D. F., et al. (2007). SNP fine mapping of chromosome 8q24 in bipolar disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, 144B, 625-630.
53. Zandi, P. P., Badner, J. A., Steele, J., Willour, V. L., Miao, K., MacKinnon, D. F., et al. (2007). Genome-wide linkage scan of 98 bipolar pedigrees and analysis of clinical covariates. Molecular Psychiatry, 12, 630-639.
54. Zandi, P. P., Belmonte, P. L., Willour, V. L., Goes, F. S., Badner, J. A., Simpson, S. G., et al. (2008). Association study of Wnt signaling pathway genes in bipolar disorder. Archives of General Psychiatry, 65, 785-793.
55. Zeman, M. V., Hiraki, L., & Sellers, E. M. (2002). Gender differences in tobacco smoking: Higher relative exposure to smoke than nicotine in women. Journal of Women's Health and Gender-Based Medicine, 11, 147-153.